EcN associates with Galunisertib through increasing the levels of IFN‐γ+ CD8+ cells and DCs in tumor‐draining lymph modes along with attenuating Foxp3+ Tregs and IL‐10 in tumors.[158]. Here, CD8A is linked to neoplasm.